Invirsa
Columbus
About Invirsa
Invirsa is developing a unique, broad platform based on a naturally occurring small molecule (INV-102) that has demonstrated enhanced immune response to infection. INV-102 not only reduces viral infection, and potentially bacterial replication, it also reduces inflammation, while enhancing the bodies wound healing response. Invirsa's technology is first being developed in the ophthalmology and pulmonary space. Invirsa’s technology has the potential to be a first line therapy for common infectious diseases, whether it's the 100 million viral pulmonary infections or the 5 million infectious conjunctivitis cases that occur every year in the US alone.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $16.1M
- Funding stage: Early Stage Venture
- Last round: Series B (Jun 2023)
- Website: invirsa.com
- Phone: 614-715-1860
Industries & Categories
Biotechnology, Health Care, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/invirsa-81424 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.